57AA1143-0FA1-4197-8CBE-517F6B885753
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 43.856767411300915
- age_years
- 44
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.671
- INTERFERON_GAMMA_RESPONSE+0.525
- MYC_TARGETS_V1+0.465
- NOTCH_SIGNALING+0.445
- DNA_REPAIR+0.377
- G2M_CHECKPOINT+0.370
- PROTEIN_SECRETION+0.366
- E2F_TARGETS+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.360
- ALLOGRAFT_REJECTION+0.356
Top 10 suppressed
- MYOGENESIS-0.346
- KRAS_SIGNALING_DN-0.278
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.255
- PANCREAS_BETA_CELLS-0.241
- SPERMATOGENESIS-0.229
- ANGIOGENESIS-0.176
- HYPOXIA-0.135
- ESTROGEN_RESPONSE_LATE-0.133
- COAGULATION-0.108
- TNFA_SIGNALING_VIA_NFKB-0.078
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 37E6F027-C405-4671-80BD-CC40684DE803 | — | — | 0.932 |
| 2 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.922 |
| 3 | E16AD7E1-29DA-4B8F-8B12-A8A6BBAA9174 | — | — | 0.914 |
| 4 | AAD8D181-FDC2-4722-B5CD-45344E0905E0 | — | — | 0.908 |
| 5 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.904 |
| 6 | SRR934819 | — | — | 0.895 |
| 7 | 4880B586-BA92-48B2-A233-5C245D2E31C0 | — | — | 0.893 |
| 8 | C9523C23-CF9B-4C33-A256-4106AD46729D | — | — | 0.888 |
| 9 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.886 |
| 10 | C81B24AB-2DBA-4624-A1D4-D4DCAC714506 | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.671 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.525 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.465 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.445 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.377 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.366 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.356 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.353 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.345 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.319 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.307 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.294 | Remibrutinib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.274 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.273 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.267 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.242 | Inavolisib | — uncovered |